NL-OMON31559尚未招募不适用
Determination of the pharmacokinetics of rituximab and antibodies to rituximab in patients with a B-cell CD20+ malignancy who are treated with rituximab as single agent or rituximab in combination with chemotherapy or are on maintenance therapy with rituximab - Pharmacokinetics and antibodies rituximab during standard treatment
Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 40 人开始时间: 待定最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 发起方
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Observational
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •· All patients with a CD20+ B-cell malignancy who are treated with rituximab are eligible for this study.
- •· Written informed consent
排除标准
- •no written informed consent
研究者
相似试验
进行中（未招募）
1 期
Pharmacokinetic study of rituximab induction regimen in ANCA-associated vasculitisEUCTR2015-001807-29-FRCHU de Saint-Etienne50
未知
2 期
Clinical study for effectiveness of rituximab for acquired coagulopathyacquired coagulopathyJPRN-UMIN000024612Gunma University10
已完成
不适用
A study of the efficacy and safety to rituximab in treating adult onset refractory nephrotic syndromeRefractory nephrotic syndromeJPRN-UMIN000021143Fujita Health University School of Medicine, Department of Nephrology10
已完成
不适用
Rituximab therapy for refractory pemphigusJPRN-jRCTs031180405Funakoshi Takeru20
招募中
不适用
Safety evaluation study about rituximab therapy for refractory pemphiguspemphigusJPRN-UMIN000026004Keio University, School of Medicine20